Known targets — ChEMBL curated mechanism
CYP11A1CYP11B1CYP11B2CYP17A1ERG11
The experimentally established mechanism targets of Levoketoconazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 known ✓ | P05093 | 15/20 | 0.79 |
| ▸ | CYP11B1 known ✓ | P15538 | 14/20 | 0.79 |
| ▸ | CYP11B2 known ✓ | P19099 | 1/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 19/20 | 0.79 |
| ▸ | CYP21A2 | P08686 | 16/20 | 0.79 |
| ▸ | CYP19A1 | P11511 | 16/20 | 0.79 |
| ▸ | USP2 | O75604 | 2/20 | 0.79 |
| ▸ | MAPT | P10636 | 2/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.79 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.79 |
| ▸ | CYP27B1 | O15528 | 1/20 | 0.79 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.79 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.79 |
| ▸ | GMNN | O75496 | 1/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ketoconazole SCHEMBL28114738 | 1.00 | CYP3A4 (0.79) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL15864759 | 0.95 | CYP3A4 (0.80) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Ketoconazole SCHEMBL6692835 | 0.94 | CYP3A4 (0.75) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL20775122 | 0.92 | CYP3A4 (0.67) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL24312989 | 0.89 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL41473 | 0.89 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL1517472 | 0.89 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Ketoconazole SCHEMBL8408 | 0.89 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Ketoconazole SCHEMBL18258319 | 0.89 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL8407 | 0.89 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1594546-A1 | SALICYLIC ACID DERIVATIVE AS EFFICACY ENHANCER AND METHOD | L'OREAL (FR) | 2005-11-16 | — | — | EP | claimed |
| WO-2004073745-A1 | SALICYLIC ACID DERIVATIVE AS EFFICACY ENHANCER AND METHOD | L'ORÉAL (FR) | 2004-09-02 | — | — | WO | claimed |
| US-20040162272-A1 | Chemical enhancer and method | L'OREAL S.A. (FR) | 2004-08-19 | — | — | US | claimed |
| US-9585846-B2 | Anti-microbial composition | WILD CHILD (AU) | 2017-03-07 | — | — | US | disclosed |
| EP-2205230-B1 | ANTI-MICROBIAL COMPOSITION | WILD CHILD (AU) | 2016-03-23 | — | — | EP | disclosed |
| US-20150064288-A1 | Anti-Microbial Composition | WILD CHILD (AU) | 2015-03-05 | — | — | US | disclosed |
| US-8859627-B2 | Anti-microbial composition | WILD CHILD (AU) | 2014-10-14 | — | — | US | disclosed |
| US-8343519-B2 | Enhancing the efficacy of an active agent in or on the body, comprising applying to the body a combination of an active agent and at least one salicylic acid derivative | L'OREAL S.A. (FR) | 2013-01-01 | — | — | US | disclosed |
| US-20110028563-A1 | ANTI-MICROBIAL COMPOSITION | WILD CHILD (AU) | 2011-02-03 | — | — | US | disclosed |
| EP-2205230-A1 | ANTI-MICROBIAL COMPOSITION | Wild Child (AU) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009052566-A1 | ANTI-MICROBIAL COMPOSITION | WILD CHILD (AU) | 2009-04-30 | — | — | WO | disclosed |
| EP-1594546-A1 | SALICYLIC ACID DERIVATIVE AS EFFICACY ENHANCER AND METHOD | L'OREAL (FR) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004073745-A1 | SALICYLIC ACID DERIVATIVE AS EFFICACY ENHANCER AND METHOD | L'ORÉAL (FR) | 2004-09-02 | — | — | WO | disclosed |
| US-20040162272-A1 | Chemical enhancer and method | L'OREAL S.A. (FR) | 2004-08-19 | — | — | US | disclosed |
| US-4542020-A | CELLULOSE DERIVATIVE HYDROCOLLOID, LOW MELTING BASE | E. R. SQUIBB & SONS, INC. (US) | 1985-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162272-A1 | Chemical enhancer and method | ALOX5, TYR, ALOX15 | CYP17A1 104/4885CYP11B1 1432/4885CYP11B2 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.